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Background: The catechol-O-methyltransferase (COMT) enzyme has been widely studied due to its multiple roles in
neurological functioning, estrogen biology, and methylation metabolic pathways. Numerous studies have investigated
variation in the large COMT gene, with the majority focusing on single nucleotide polymorphisms (SNPs). This
body of work has linked COMT genetic variation with a vast array of conditions, including several neurobehavioral
disorders, pain sensitivity, and multiple human cancers. Based on COMT’s numerous biological roles and recent
studies suggesting that methylation of the COMT gene impacts COMT gene expression, we comprehensively
interrogated methylation in over 200 CpG dinucleotide sequences spanning the length of the COMT gene.
Methods: Using saliva-derived DNA from a non-clinical sample of human subjects, we tested for associations between
COMT CpG methylation and factors reported to interact with COMT genetic effects, including demographic factors
and alcohol use. Finally, we tested associations between COMT CpG methylation state and COMT gene expression in
breast cancer cell lines. We interrogated >200 CpGs in 13 amplicons spanning the 5’ UTR to the last exon of the CpG
dinucleotide-rich COMT gene in n = 48 subjects, n = 11 cell lines and 1 endogenous 18S rRNA control.
Results: With the exception of the CpG island in the 5’UTR and 1st exon, all other CpG islands were strongly
methylated with typical dynamic ranges between 50-90%. In the saliva samples, methylation of multiple COMT loci was
associated with socioeconomic status or ethnicity. We found associations between methylation at numerous loci
and genotype at the functional Val158Met SNP (rs4680), and most of the correlations between methylation and
demographic and alcohol use factors were Val158Met allele-specific. Methylation at several of these loci also
associated with COMT gene expression in breast cancer cell lines.
Conclusions: We report the first comprehensive interrogation of COMT methylation. We corroborate previous findings
of variation in COMT methylation with gene expression and the Val158Met genotype, and also report novel associations
with socioeconomic status (SES) and ethnicity at several methylated loci. These results point to novel mechanisms for
COMT regulation, which may have broad therapeutic implications.Background
Catechol-O-methyltransferase (COMT) enzyme has broad
biological functions, principally the catabolism of biologic-
ally active or toxic catechols, including catecholamines
and catecholestrogens [1]. As a result of its ubiquity,
COMT has been implicated in a wide range of human* Correspondence: tswift@unc.edu; cab@unc.edu
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article, unless otherwise stated.conditions, including cancer [2], pain sensitivity [3,4],
schizophrenia [5], affective [6], addictive [7,8], impulse
control disorders [9], and Parkinson’s disease [10]. The
clinical significance of these conditions has stimulated
growing interest in COMT in recent decades, particularly
following the discovery that COMT enzyme activity level
in human tissues is genetically polymorphic, conferring
low, intermediate, and high activities [11,12]. A great deal
of research has focused on a common, functional, single
nucleotide polymorphism (SNP) of COMT, Val158Met
(rs4680), that is the most studied variant, due to its loca-
tion within the exon 4 coding region. Specifically, theentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ition 158 results in three- to four-fold reduced activity of
the COMT enzyme due to reduced protein stability
[13-15]. COMT is the primary regulator of dopamine
clearance in extrastriatal brain regions, including the pre-
frontal cortex [16-18], which has helped to motivate re-
search into associations of Val158Met with neuropsychiatric
disorders since the mid-1990’s [19]. Early neuroimaging
studies found the COMT 158Val allele to be associated with
impaired prefrontal cognition and physiology, which could
contribute to schizophrenia risk [5], and to modulate pain
perception and brain responses to pain [4]. However, ob-
served associations between various conditions and the
158Val allele are modest and often inconsistent. Thus, more
recent work has identified COMT haplotypes that are asso-
ciated with more profound changes in COMT activity, in
part by effects on COMT protein expression [20,21].
Finally, other studies have tried to shed light on addi-
tive contributions to disease state by considering COMT
polymorphisms in combination with other polymorphic
gene loci. For example, genotype × genotype analyses in-
volving COMT Val158Met with the methylenetetrahy-
drofolate reductase (MTHFR) C677T polymorphism have
shown strong interactive effects associated with elevated
total plasma homocysteine in a case control study of
elders with and without dementia [22] as well as on
dopamine signaling [23], executive function [24], and
cognition [25] in persons with schizophrenia. COMT ×
MTHFR and other multigene interactions have also been
explored in breast cancer [26-28].
In addition to the reported genetic effects on COMT
expression, activity, brain function, and associations with
behavior or disease risk, several non-genetic factors have
been reported to impact COMT function, either in isola-
tion or via interactive effects on genetic associations.
These include an age-dependent rise in COMT activity in
the prefrontal cortex [29], interacting effects of Val158Met
genotype and age on impulsive choice [30], and sexually
dimorphic associations with COMT in humans [31,32].
In addition, numerous studies have reported interac-
tions between Val158Met genotype and environmental
stressors, impacting everything from prefrontal function
[33], and affect-modulated startle [34], to risk of alcohol-
ism [35], posttraumatic stress disorder [36,37], and im-
pulsive aggression [38]. How these non-genetic factors
modulate COMT effects is largely unknown, but epigen-
etic regulation at the level of DNA methylation is one
potential mechanism. In fact, investigations of the asso-
ciation between alcohol use and DNA methylation is a
rapidly expanding area of research, although no studies
to date have specifically investigated methylation within
the COMT gene, beyond a few CpGs [39].
COMT polymorphisms have been broadly explored,
not only within neurobiology, but also for their role incarcinogenesis, particularly in hormonally distinct can-
cers of the uterus and breast [2,31,40]. As in multiple
neurobiobehavioral studies, the associations between
COMT Val158Met and breast cancer risk have been in-
consistent or modest [41-43]. One meta-analysis of
COMT Val158Met based on more than 30,000 cases and
38,000 controls, found an increased risk for breast can-
cer only when the sample was stratified by race [44].
Given the predominance of estrogen receptor negative
breast cancer in African American women, it is plausible
that the He et. al. (2012) finding may more precisely re-
flect varied COMT influences that are dependent on the
estrogen receptor status of the tumor.
The rationale for studying the influence of COMT on
hormonally influenced cancer relates to the role of
COMT on catecholamines and in estrogen metabolism.
Specifically, the catecholamine neurotransmitters dopa-
mine, norepinephrine, and epinephrine are synthesized
primarily in the adrenal glands, and are derived metabol-
ically from the amino acids tyrosine and phenylalanine
[45]. The COMT enzyme effects the degradation of both
catecholamines and catecholestrogens (important inter-
mediary metabolites in estrogen induced cancers), by the
addition of a methyl group [46]. The methyl (CH3)
group with which COMT carries out targeted destruc-
tion of catechol compounds is provided by S-adenosyl
methionine (SAM), a key methyl donor in the folate
metabolic pathway with a pivotal role in epigenetic alter-
ations in general, [45] and in epigenetic changes in can-
cer in particular [47,48].
Past studies have focused on genetic variations, par-
ticularly SNPs as vulnerability factors for cancer [40,44],
schizophrenia [5], pain [49], emotional processing [50],
and broad cognitive functioning [51]. While the discov-
ery of COMT genetic polymorphisms has illuminated a
host of biologic vulnerabilities ranging from cancer to
neurobehavioral pathology, recent evidence suggests that
epigenetic changes, particularly DNA methylation of
CpG (e.g., “C – phosphate - G” on the same DNA
strand) dinucleotide sequences in the COMT gene, may
also have an important impact on COMT function
[52,53]. DNA methylation may be inherited (via imprint-
ing for example), and/or may result from somatic
changes due to a wide array of environmental influences,
such as exposure to stress [54], diet, alcohol and tobacco
use [47,48]. Once effected, somatic DNA methylation
changes are perpetuated in successive cell generations dur-
ing cell replication and division [55]. DNA methylation can
affect gene transcription via interactions with DNA pack-
aging chromatin proteins, and/or by interfering with the
binding of enhancers, transcription factors, or other pro-
teins involved in transcriptional regulation [15]. In such
cases, DNA methylation may exert its effects either syner-
gistically or independent of known genetic variations.
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tial COMT DNA methylation [56], and associations be-
tween COMT methylation state and vulnerabilities to a
spectrum of conditions ranging from schizophrenia
[57,58] to the cognitive effects of stress [33], we sought
to provide the first comprehensive assessment of DNA
methylation throughout the COMT gene, simultaneously
considering Val158Met genotype in association with methy-
lation changes. We hypothesized that differential methyla-
tion (DM) would be associated with demographic factors,
reflecting a possible environment × gene interaction, and
with variation in COMT genotype, which would support
COMT allele-specific methylation. Moreover, we hypothe-
sized that different levels of alcohol use would also be asso-
ciated with COMT methylation, possibly in a COMT
genotype-dependent manner. We tested these hypotheses
using saliva samples collected from a non-clinical commu-
nity sample of adult social drinkers (ages 18–40) with no
known history of neurologic or psychiatric illness, and a
spectrum self-reported alcohol use. The epigenetic vari-
ation in peripheral COMT detected in DNA derived from
human saliva has been shown to be similar to those found
in COMT in the brain [58]. In addition, we were able to
test for associations between COMT DM and observed
variation in COMT gene expression in breast cancer cell
lines. We interrogated over 200 CpGs in 13 amplicons
spanning the 5’ UTR to the last exon of the CpG
dinucleotide-rich COMT gene in n = 48 subjects, n = 11
cell lines and 1 endogenous 18S rRNA control. We report
DM at multiple COMT loci in association with Val158Met
genotype, socioeconomic status (SES), ethnicity, alcohol
use, and gene expression.
Methods
Sample characteristics
Participants (n = 48) were recruited from the University
of North Carolina, Chapel Hill (UNC) and surrounding
community. Participants were healthy individuals 18–40
years old with no known past or present neurological or
psychiatric diagnoses, no history of substance use disor-
ders, and no current use of psychoactive medications or
other psychoactive substances aside from moderate caf-
feine, nicotine or alcohol. All subjects were native English
speakers, had at least a high-school education, and re-
ported having consumed alcohol at least once in their life-
time. Information regarding participants’ occupation and
education was collected via a questionnaire and quantified
based on the method of Hollingshead [59]. Participants
gave written informed consent, as approved by the UNC
Office of Human Research Ethics.
General procedure
Participants completed questionnaires to allow quantifi-
cation of SES according to Hollingshead [59]. We alsocollected data regarding each participant’s alcohol use
via the Alcohol Use Disorders Identification Test [60].
Saliva samples: DNA extraction and genotyping
COMTVal158Met (rs4680) genotyping was performed
on DNA extracted from saliva samples (DNA Genotek,
Kanata, Ontario, Canada) using TaqMan technology
(Life Technologies, Foster City, CA), as described previ-
ously [61]. Genotyping was performed by the Duke
Center for Human Genetics. Allele frequencies in this
sample did not deviate from Hardy–Weinberg equilib-
rium (x2 = 1.91, df = 1, p = 0.17).
Sodium bisulfite conversion of DNA
Like many methylation assays, the EpiTYPER assay
hinges on an initial PCR reaction using primers specific
to sodium bisulfite (NaBi) converted DNA, wherein all
un-methylated cytosines are converted to uracil, then
subsequently to thymine during PCR. Conversely, meth-
ylated cytosines (e.g., CpG dinucleotides) are not con-
verted, and thus allow assessment of the true methylated
state of the interrogated loci prior to NaBi conversion.
The EZ DNA Methylation-Direct Kit (Zymo Research,
Irvine, CA, USA) was used to sodium bisulfite convert
genomic DNA extracted from cell lines or saliva sam-
ples. Sodium bisulfite conversion was performed on a
thermocycler at 95°C for 30 s and 50°C for 15 min for
twenty cycles as per protocol.
Quantifying COMT methylation using the EpiTYPER
MassARRAY Platform
Percent methylation was quantified throughout the COMT
gene using mass spectrometry with the EpiTYPER® T
complete reagent kit as previously described [62]. The
SEQUENOM EpiTYPER® methylation assay has been vali-
dated in numerous studies and previously described in de-
tail [63-65]. We custom designed primer sets specific for
sodium bisulfite converted DNA for 13 amplicons span-
ning 5’ of exon 1 to the 3’ end of COMT located in exon 6
(Figure 1, Table 1). The 13 amplicons were chosen because
they either assayed a CpG island as defined by a CpG
content greater than 50% spanning 300 bp or more, and/or
because they allowed interrogation of CpG sequences
located in important regulatory COMTgene regions.
PCR of all 13 COMT amplicons was carried out on 10
ng of NaBi converted genomic DNA in 5 μl reaction vol-
umes under the following conditions: 95°C for 2 min, with
a series of touch down reactions for 2 cycles at 95°C for
30 s, 60°C for 30 s, 72°C for 1 min, 2 cycles each with a
59°C, 58°C and 57°C annealing, respectively, followed by
40 cycles at 56°C annealing. The PCR product (2 μl) was
added to 5 μl of the T-Cleavage reaction as a template for
the in vitro transcription reaction as per the EpiTYPER
protocol. The final T cleavage reaction produced un-
Figure 1 COMT gene features relative to amplicons interrogated for methylation. COMT spans ~32 kb (chromosome 22q11.21, human
build NCBI 37/hg 19, bp 19925733 – 19957832), with two major transcript variants encoding soluble and membrane bound (S-COMT and MB-COMT)
enzyme forms, respectively (drawn to scale). 13 amplicons (001–013, orange arrows), were designed to interrogate methylation in CpG islands (blue
cylinders) throughout COMT. Previously identified SNPs associated with impulsivity or pain sensitivity are listed by rs number (red font), with
approximate SNP position indicated by blue vertical arrows. Top row: The S-COMT variant is encoded by four exons (black lined white boxes),
regulated by promoter P1 (green bar), and possibly by a predicted promoter (PP) 5’ of P1. Bottom Row: The MB-COMT is encoded by 6 exons
(with multiple possible variants of exon 1 (1-v1, 1-v2, 1-v3). Expanded view (dashed diagonal lines), highlight three ~40 bp repeat sequence motifs that
we identified spanning ~1.5 kb beginning in exon 1-v2 through intron 1; the ATG1 and ATG2 translational start sites (TSS) in Exon 3 for S-COMT and
MB-COMT, respectively; and the rs4680 SNP in Exon 4 encoding the substitution of valine (val) with methionine (met) at codon 158.
Table 1 COMT amplicon description
Amplicon
name
Human build 37 Length CpG
Position, Chr. 22 BP Coverage
COMT_001 19928951 400 37
COMT_002 19938388 418 17
COMT_003 19938762 371 13
COMT_004* 19940043 226 8
COMT_005 19946527 438 20
COMT_006 19949994 392 16
COMT_007* 19955930 379 14
COMT_008 19949536 484 11
COMT_009* 19950497 405 11
COMT_010 19951020 277 14
COMT_011* 19951513 455 11
COMT_012* 19931875 379 17
COMT_013 19935171 394 14
COMT amplicons 001 – 013 are listed together with their human build NCBI
37/hg 19 bp location on chromosome 22. Amplicon size (in bp), together with
the number of CpGs interrogated for methylation are provided. *amplicons
were not differentially methylated, or could not be reliability amplified due to
repetitive DNA sequence in the region (COMT_004, see Figure 1).
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http://www.biomedcentral.com/1755-8794/7/5methylated and methylated CG containing fragments that
were resolved and quantified for percent methylation via
mass spectrometry. We discovered that COMT_004
would not amplify efficiently due to stuttering of the Taq
polymerase through flanking repetitive sequences in the
region (Figure 1), and it was therefore excluded from fur-
ther analyses. Similarly, COMT_007, 009, 011 and 012
were not differentially methylated in our initial sample set
and therefore were not included in subsequent analyses.
Cell line gene expression
Breast cancer cell lines were cultured as described previ-
ously [62]. Gene expression in breast cell lines was
quantified using qRT-PCR on a 7500 Real-Time PCR
Platform (Life Technologies, Foster City, CA). Relative
cDNA quantity was measured using pre-designed ABI
TaqMan probes and primers for COMT (COMT-
Hs00241349_m1) and 18S rRNA (18S rRNA −4333760-
1007035_g1) as the endogenous expression control (Life
Technologies). Cell line cDNAs were examined in tripli-
cate, with qRT-PCR cycling as follows: 50°C for 2 min,
denaturation at 95°C for 10 min, followed by 40 cycles
of 95°C for 15 s, and 60°C annealing for 1 min. The only
commercially available COMT TaqMan probe does not
distinguish S and MB transcript variants.
Statistical Analyses Values reported as mean ± SEM, un-
less otherwise stated. Statistical analyses performed in SPSS
(IBM Corp., Armonk, NY), except where otherwise noted.Hierarchical clustering analysis
We first performed unsupervised hierarchical clustering
using MeV (version 4.8.1) of the TM4 software suite [16]
with complete linkage, Euclidean distance parameters se-
lected for COMT percent methylation values in the
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Figure 2 Hierarchical clustering analysis of COMT methylation in the UNC dataset. The clustergram is highlighted on the left to display the
major clada or related groups of methylated CpGs for each dataset. Percent methylation is represented on a color continuum of bright yellow (0%),
black (50%) to bright purple (100%). Colored bars on the right of the clustergram display the amplicon members of each group. (COMT_001 = dark
blue, COMT_002 = salmon, COMT_003 = purple, COMT_005 = yellow, COMT_006 = purple, COMT_008 = green, COMT_010 = light blue, COMT_013 = red).
Unsupervised hierarchical clustering analysis (HCA) by CpG unit of A 48 subjects and 110 CpGs shows 3 groups of subjects by COMT Val158Met
genotype, age, sex, and alcohol use (AUDIT score). Group A is enriched for VV +MV genotypes, Group B for MM+MV genotypes and high AUDIT
scores, and Group C for VV +MM genotypes. B Clustergram reveals the 39 most differentially methylated CpGs after applying a 40% standard
deviation filter, after which Group C becomes predominantly VV genotype enriched.
Table 2 Demographic data
(n = 48)
Age (yrs) 25 ± 6
Education (yrs) 16 ± 2
SES 45 ± 10
Sex (% female) 52.1
Ethnicity (% white) 72.9
Black (%) 12.5
Hispanic (%) 4.2
Asian (%) 6.3
Other/mixed (%) 4.2
AUDIT score 7.9 ± 5.4
Values are reported as mean ± standard deviation. AUDIT, Alcohol Use
Disorders Identification Test; SES, socioeconomic status.
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http://www.biomedcentral.com/1755-8794/7/5UNC dataset (Figure 2A). In order to identify the most
differentially methylated CpGs in COMT amplicons 001,
002, 003, 005, 006, 008, 010, and 013, we applied a 40%
standard deviation filter with the MeV application
(Figure 2B).
Robust partial correlation analysis
To eliminate concerns regarding violation of parametric
test assumptions, bootstrapping procedures (n = 1000
resamples) were used in tests of statistical significance.
We calculated partial correlation Pearson coefficients in
models for demographic factors and COMT methyla-
tion. To evaluate the relationship between COMT
methylation and gene expression in cell lines, we calcu-
lated Spearman’s rho correlations due to the skewed dis-
tribution of gene expression data. Correction of p-values
for multiple comparisons using the false discovery rate
(FDR) procedure [66] was carrying out in R (http://www.
R-project.org).
Results
Sample characteristics
Healthy participants ages 18–40 (n = 48) provided a sal-
iva sample from which DNA was extracted for COMT
Val158Met genotyping and COMT gene methylation ana-
lysis. The sample was well educated and predominately
white, and was balanced in terms of sex and light or
heavy social drinking (see Table 2).
Characterization of methylation sites within the COMT
gene
Figure 1 highlights the COMT gene structures which en-
code the two major protein variants; the soluble (S-COMT)
and membrane-bound (MB-COMT) forms, respectively.
Table 1 describes the specific location and relevant features
for the 13 amplicons interrogated. We performed unsuper-
vised hierarchical clustering analysis (HCA) on percent
methylation values for CpGs throughout COMT based
on Euclidean distance and complete linkage mapping
(Figure 2A). In order to identify the most differentially
methylated CpGs, we applied a standard deviation (SD)
filter of 40% and obtained the most informative CpGs
for the UNC dataset (Figure 2B). HCA of DNA methyla-
tion throughout COMT revealed 3 distinct groups orclada relative to the Val/Met genotypes (Val/Val +Met/Val
mix, Met/Met +Met/Val mix, and a Val/Val enriched
group). With the exception of the CpG island in the
5’UTR and 1st exon, all other CpG islands were strongly
methylated with a dynamic range of methylation typically
between 50-90%.
Figures 3A-3C are “epigrams” which serve to illustrate
percent methylation variance per CpG unit across three
selected amplicons; COMT_001, 005 and 006. These
amplicons were chosen because they showed CpG unit
methylation variability across sample types. As seen in
Figure 3A, COMT_001 is relatively hypomethylated
(with colored circles in the yellow continuum indicating
percent methylation values of 20 percent or less), for
breast cancer cell lines, and for three of the saliva samples.
Differentially methylated CpG units, when they occur, are
observed for CpGs 1, 3, 4, and 34 in the COMT_001
amplicon (Figure 3A). Conversely, COMT_005 and 006
(Figures 3B-3C), are relatively hypermethylated. Notably,
both COMT_005 and 006 are differentially methylated be-
tween biologically distinct basal and luminal breast cancer
cell lines. Moreover, methylation variance, when and if it
occurs, begins well into the amplicon at CpG 8 or 7 for
the 005 and 006 amplicons, respectively. COMT DNA
Methylation derived from saliva samples from healthy
adults display a wholly different pattern from cell lines,
AB
C
Figure 3 Epigrams of amplicons illustrate variable methylation by sample type. The Sequenom EpiTYPER MassARRAY platform was used
to calculate percent methylation for CpG dinucleotides within each of the three amplicons shown. The epigram schematic illustrates percent
methylation for each consecutive CpG (colored circle) on a continuum from yellow (0%) to navy blue (100%). Shaded circles represent CpGs that
could not be quantified because they fell outside the Mass Dalton allowable detection window of the EpiTYPER software. Twelve samples per
amplicon are shown to illustrate differential methylation: Rows 1–6 represent two groups of biologically distinct breast cancer cell lines (three
basal-like and three luminal breast cancer cell lines respectively). Rows 7–12 are from six different healthy saliva samples. A. Amplicon COMT_001
is located in the CpG island 5’ and including exon 1 (Figure 1) and is relatively hypomethylated, with CpGs 1,3,4, and 34 showing the most
heterogeneity across sample type. B. Amplicon COMT_005, located in the CpG island within the predicted promoter (P*) for S-COMT, is relatively
hypermethylated for CpGs 1–7 for all samples, and most differentially methylated between CpGs 8–18 as illustrated by breast cell line samples
T47D & MCF7, & saliva sample YAD189. C. Amplicon COMT_006, is located in Exon 3 (Figure 1), and like COMT_005, is homogeneously methylated at
the beginning of the amplicon (CpGs 1–6), with differential methylation occurring between CpGs 7–16, as evidenced by relative hypermethylation of
these loci in the basal versus the luminal cell lines.
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http://www.biomedcentral.com/1755-8794/7/5with CpGs 8–17 for amplicon 005, and CpGs 3, 4, 8, 10
and 13 for amplicon 006 showing the most percent
methylation variability. Note that in 2005, Murphy and
colleagues interrogated 6 CpGs that fall within ouramplicons 006 and 008, finding that our COMT_006,
CpG #3 (Figure 3C) was the most differentially methylated
in a mixed sample of patients with schizophrenia and un-
affected siblings [56].
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COMT gene
Percent methylation of CpG units within the COMT
gene by individual sample characteristics is presented in
Table 3. Within the full sample, no significant differ-
ences in COMT methylation were found to associate
independently with age, sex, or alcohol use, when con-
trolling for effects of other factors, which also included
COMT Val158Met genotype, SES, and ethnicity. Relative
to non-white participants, whites had significantly greater
methylation at CpG 003_1 (r = .421, 95% CI: .103, .696,
p = .008). Whites also had significantly less methylation
at CpG 006_3 (r = −.336, 95% CI: -.644, .051, p = .039),
which is located in exon 3, the exon containing both
ATG translational start sites for S- and MB-COMT var-
iants, and the locus previously reported to show high
DM across individuals [56]. We also observed a signifi-
cant negative correlation between SES and methylation
at CpG 001_34 (r = −.331, 95% CI: -.653, .044, p = .049).
In contrast to these sporadic and mostly weak effects,
we found that numerous CpG’s within the COMT gene
were DM by genotype at the Val158Met (rs4680) SNP,
with all but one (008_3) showing reduced methylation
with increasing numbers of 158Met alleles. CpGs within
amplicons 005 and 006 were particularly affected, with
additional sites in amplicons 008 and 010. Notably, two
of our observed correlations survived FDR correction
for multiple comparisons (alpha = .05): 006_8, and
008_3. As seen in Figure 1, these amplicons fall within
a region of the gene dense with CpG islands, with
amplicon 010 including the Val158Met SNP (Figure 1).
When considering Val allele carriers and Met allele
carriers separately, we found significantly greater methy-
lation in whites relative to non-whites at CpG 003_1 in
both groups (both p = .009). In contrast, we observed
significantly less methylation among whites at CpG
006_3 among Met carriers (r = −475, p = .026), but not
among Val carriers (−.302, p = .105). In addition, signifi-
cant hypomethylation of CpGs in amplicons 005, 006,
008, and 010 were observed among white relative to
non-white Met carriers, but not Val carriers. In fact, we
saw significant hypomethylation of each DM CpG in
amplicon 010 among white relative to non-white Met car-
riers (010_avg: r = −.551, 95% CI: -.832, -.023, p = .008),
which was not evident among Val carriers (010_avg:
r = −.147, 95% CI: -497, .261, p = .439). The DM at
CpG 001_34 associated with SES was also COMT
allele-specific: we observed a significant association
between SES and DM among Met carriers (r = −.447, 95%
CI: -.721, -.025, p = .042), but not Val carriers (r = −.258,
95% CI: -.643, .261, p = .185). After accounting for the
effects of other factors, we did not observe any significant
correlations between methylation and age or sex specific
to Val or Met carriers.In addition, numerous studies have reported interac-
tions between Val158Met genotype and environmental
stressors, on risk of alcoholism [35]. Although data from
human postmortem brain samples has shown less global
DNA methylation in the brains of alcoholics relative to
controls [67], we found no correlation between methyla-
tion and alcohol use in the sample as a whole when con-
trolling for effects of the other factors. Among Met
carriers, however, we did find significant hypomethylation
of amplicon 001 with increasingly hazardous alcohol use
(001_avg: r = −.435, 95% CI: -.728, -.114, p = .049); no such
relationship was observed among Val carriers (001_avg:
r = −.038, 95% CI: -.473, .381, p = .847). Qualitatively
similar results were obtained when participants were
dichotomized according to whether they were “possible
hazardous drinkers” or not, based on AUDIT scores
[60] (data not shown).
Relationship between methylation of COMT and COMT
gene expression in breast cancer cell lines
To evaluate the functional consequences of methylation
at particular CpGs within COMT, we evaluated the ef-
fects of methylation on COMT expression in a sample
containing both estrogen receptor positive and negative
breast cancer cell lines by quantitative real-time reverse
transcription-PCR (qRT-PCR). As expected, COMT
DNA methylation in human cell lines was inversely cor-
related with COMT mRNA expression at several loci.
Specifically, COMT gene expression was negatively cor-
related with percent methylation in all of the DM CpGs
within amplicon 006 (see Table 4), including CpG 006_3
(r = −.683, 95% CI: -.820, .525, p = .029), a CpG within
the exon containing both ATG translational start sites
for both S- and MB-COMT, respectively (Figure 1) that
was previously reported to be DM across individuals
[56], and which was also DM within our saliva samples
from healthy controls.
Discussion
We studied DNA methylation throughout the large
COMT gene, interrogating over 200 CpG dinucleotides
spanning more than 27,000 base pairs. To our know-
ledge, this is the first comprehensive assessment of
COMT DNA methylation, and also the most compre-
hensive test of associations between such methylation
and non-genetic factors, the Val158Met genotype, and
their interactions. With the exception of the hypomethy-
lated amplicon 001 covering part of the 5’UTR and exon
1 of COMT (Figure 1), the remaining 12 amplicons were
relatively hypermethylated, with an observed dynamic
range of methylation typically between 50–90 percent.
By employing the use of the EpiTYPER® MassARRAY
platform to precisely quantify methylation for each CpG
unit, we were able to pinpoint specific, differentially
Table 3 COMT methylation in healthy human subjects versus individual factors
CpG Units Age Sexa AUDIT score Ethnicityb SES COMTMet alleles
r (95% CI) p
001_1 -.099 (−.401, .390) .565 .071 (−.397, .357) .681 -.021 (−.461, .381) .905 -.124 (−.556, .247) .470 .039 (−.236, .262) .821 .003 (−.381, .474) .988
001_3.4 -.022 (−.241, .292) .901 -.051 (−.331, .313) .766 -.085 (−.411, .336) .612 -.187 (−.454, .216) .274 -.137 (−.546, .164) .425 -.084 (−.322, .331) .624
001_34 .037 (−.221, .355) .830 -.081 (−.352, .243) .639 -.206 (−.543, .110) .227 -.201 (−.568, .166) .239 -.331 (−.653, .044) .049* -.018 (−.290, .336) .919
001_avg -.029 (−.256, .265) .865 -.034 (−.348, .223) .845 -.169 (−.482, .158) .323 -.235 (−.520, .146) .168 -.232 (−.521, .065) .174 -.037 (−.358, .343) .830
002_1 -.051 (−.373, .284) .768 .058 (−.258, .415) .737 .038 (−.263, .386) .825 .195 (−.134, .528) .256 -.189 (−.479, .124) .269 .130 (−.214, .454) .451
002_5 .073 (−.382, .440) .673 .168 (−.161, .529) .326 .038 (−.270, .338) .826 -.066 (−.386, .311) .701 -.235 (−.542, .117) .168 .282 (−.090, .600) .096
002_10 .002 (−.348, .382) .991 .081 (−.222, .434) .638 -.044 (−.351, .278) .797 .145 (−.208, .498) 398 -.222 (−454, .046) .194 .257 (−.049, .514) .130
002_avg -.009 (−.336, .338) .960 .097 (−.195, .463) .574 .009 (−.307, .324) .959 .140 (−.208, .494) 415 -.230 (−.470, .092) .177 .227 (−.100, .495) .184
003_1 -.118 (−.461, .229) .479 -.199 (−.484, .137) .231 -.052 (−.334, .230) .758 .421 (.103, .696) .008** -.081 (−260, .412) .665 .138(−.182, .423) .408
003_3 -.154 (−.415, .131) .363 .165 (−.152, .467) .329 -.099 (−.379, .222) .561 -.278 (−.520, .008) .096 .074 (−.260, .412) .665 -.013 (−.376, .308) .940
003_6 .135 (−.128, .387) .433 -.188 (−.453, .120) .272 .151 (−.146, .443) .379 -.162 (−.396, .112) .344 -.223 (−.435, .046) .190 -.092 (−.450, .291) .593
003_avg .031 (−.301, .306) .853 -.107 (−.420, .182) .522 .061 (−.252, .339) .717 -.049 (−.390, .311) .769 -.187 (−.509, .209) .260 -.013 (−.359, .352) .937
005_2 -.239 (−.555, .214) .148 .028 (−.327, .356) .866 -.159 (−.434, .156) .341 -.209 (−.503, .184) .208 .041 (−.261, .366) .806 -.333 (−.596, -.063) .041*
005_3 -.065 (−.343, .273) .700 -.125 (−.422, .201) .454 -.116 ( −.391, .203) .489 -.159 (−.447, .176) .340 -.091 (−.358, .209) .587 -.193 (−.513, .128) .247
005_5 -.127 (−.416, .236) .446 .039 (−.283, .378) .815 -.068 (−.401, .262) .685 -.144 (−.438, .197) .388 -.136 (−.398, .202) .414 -.317 (−.592, -.047) .053
005_7 -.147 (−.451, .229) .380 -.120 (−.403, .216) .922 -.072 (−.354, .229) 668 -.176 (−.444, .184) .291 -.099 (−.400, .216) .553 .265 (−.547, .039) .107
005_8 -.103 (−.407, .280) .540 -.016 (−.349, .327) .922 -.120 (−.405, .192) .474 -.234 (−.523, .142) .157 -.074 (−.351, .264) .657 -.359 (−.601, -.072) .027*
005_9 -.058 (−.405, .381) .731 -.029 (−.342, .324) .863 -.207 (−.448, .117) .213 -.196 (−.511, .146) .239 .018 (−.329, .332) .914 -.077 (−.374, .160) .646
005_10 -.059 (−.381, .298) .723 -.064 (−.388, .276) .701 -.103 (−.416, .238) .539 -.276 (−.535, .084) .094 .120 (−.177, .431) .472 -.403 (−.632, -.108) .012*
005_17 .038 (−.230, .336) .819 -.193 (−.496, .172) .245 -.144 (−.418, .135) .389 -.290 (−.551, .030) .078 .086 (−.241, .413) .607 -.383 (−.613, -.137) .018*
005_18 -.022 (−.310, .327) .897 -.181 (−.471, .153) .284 -.203 (−.478, .131) .229 -.345 (−.623, -.026) .037* .007 (−.297, .305) .968 -.379 (−.585, -.123) .021*
005_avg -.098 (−.414, .299) .558 -.083 (−.398, .234) .621 -.161 (−.435, .152) .333 -.257 (−.542, .099) .119 -.017 (−.358, .336) .921 -.325 (−.588, -.049) .046*
006_3c -.031 (−.357, .241) .856 -.037 (−.364, .320) .823 -.056 (−.347, .256) .738 -.336 (−.644, .051) .039* .158 (−.200, .480) .342 .013 (−.333, .309) .937
006_4 -.027 (−.333, .259) .873 -.099 (−.412, .263) .554 -.094 (−.242, .318) .774 -.242 (−.529, .131) .143 .152 (−.166, .567) .363 -.093 (−.410, .225) .580
006_7 -.060 (−.365, .221) .722 .079 (−.241, .392) .638 .048 (−.242, .318) .774 -.179 (−.433, .165) .282 .122 (−.144, .361) .467 -.198 (−.514, .119) .232
006_8 -.078 (−.390, .236) .642 -.096 (−.399, .240) .566 -.043 (−.402, .311) .798 -.102 (−.508, .271) .542 .213 (−.100, .479) .200 -.932 (−.970, -.879) < .001***
006_9 -.052 (−.354, .264) .758 -.080 (−.399, .292) .635 -.047 (−.338, .278) .782 -.211 (−.489, .129) .204 .036 (−.243, .343) .829 -.306 (−.571, -.040) .061
006_10 .037 (−.248, .331) .825 -.065 (−.415, .258) .697 -.095 (−.392, .254) .570 -.201 (−.521, .162) .226 .127 (−.147, .405) .449 -.178 (−.471, .115) .285
006_12 -.046 (−.338, .311) .782 -.093 (−.410, .267) .579 -.046 (−.344, .300) .782 -.199 (−.467, .181) .231 .058 (−.263, .356) .731 -.295 (−.557, -.041) .072
006_13 -.077 (−.383, .255) .645 -.027 (−.354, .309) .874 .007 (−.315, .371) .968 -.112 (−.470, .267) .504 .072 (−.164, .339) .669 -.313 (−.590, -.021) .056
006_14.15 -.054 (−.359, .239) .746 -.109 (−.455, 236) .515 -.059 (−.381, .319) .723 -.188 (−.481, .175) .259 .120 (−.162, .407) .474 -.329 (−.579, -.063) .044*
006_16 -.050 (−.362, .278) .766 -.128 (−.450, .221) .445 -.019 (−.338, .308) .911 -.207 (−.494, .182) .212 .086 (−.222, .396) .609 -.337 (−.600, -.062) .039*
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Table 3 COMT methylation in healthy human subjects versus individual factors (Continued)
006_avg -.048 (−.350, .270) .776 -.065 (−.403, .266) .697 -.040 (−.348, .276) .813 -.212 (−.531, .161) .201 .120 (−.175, .395) .474 -.411 (−.638, -.163) .010*
008_3 -.109 (−.370, .195) .528 -.253 (−.557, .125) .136 -.033 (−.269, .221) .850 -.160 (−.482, .206) .351 .168 (−.194, .469) .326 .557 (.278, .738) < .001***
008_4 .199 (−.053, .411) .238 .056 (−.368, .275) .742 -.086 (−.350, .401) .613 -.203 (−.412, .097) .229 -.027 (−.247, .198) .875 .103 (−.484, .381) .543
008_6 .144 (−.175, .413) .394 .110 (−.240, .443) .516 .082 (−.210, .429) .631 -.189 (−.471, .151) .262 .007 (−.275, .322) .968 -.009 (−.340, .297) .956
008_10 .110 (−.169, .397) .516 .088 (−.256, .389) .606 .054 (−.300, .343) .751 -.205 (−.566, .186) .223 -.008 (−.347, .314) .965 -.196 (−.519, .101) .245
008_avg .078 (−.219, .352) .647 -.061 (−.375, .260) .718 -.011 (−.253, .293) .946 -.257 (−.578, .146) .125 .081 (−.197, .358) .632 .330 (−.035, .562) .046*
010_2 -.050 (−.390, .293) .765 .017 (−.351, .325) .919 -.170 (−.475, .154) .308 -.282 (−.595, .145) .086 .106 (−.228, .410) .527 -.228 (−.521, .043) .169
010_3.4 -.140 (−.41, .193) .401 -.021 (−.331, .301) .901 -.085 (−.411, .336) .612 -.202 (−.492, .196) .224 .094 (−.244, .385) .575 -.362 (−.605, -.073) .026*
010_6 -.154 (−.438, .207) .357 -.010 (−.352, .324) .954 -.146 (−.469, .173) .383 -.188 (−.506, .221) .259 .112 (−.223, .385) .502 -.317 (−.591, -.004) .053
010_8 -.159 (−.434, .166) .339 -.048 (−.381, .271) .775 -.194 (−.502, .171) .243 -.174 (−.494, .219) .295 .117 (−.229, .413) .482 -.336 (−.599, -.052) .039*
010_14d -.145 (−.414, .177) .386 .004 (−.373, .325) .980 -.168 (−.483, .180) .313 -.218 (−.501, .156) .189 .040 (−.291, .414) .814 .241 (−.142, .546) .145
010_ avg -.128 (−.432, .230) .444 -.015 (−.342, .296) .928 -.154 (−.495, .192) .356 -.220 (−.555, .182) .185 .110 (−.238, .395) .509 -.318 (−.587, -.031) .052
Pearson partial correlation coefficients were calculated using a bootstrapping procedure based on percent methylation values for COMT CpG units within the top 40th percentile for differential methylation within
the healthy human sample. Correlations in each column controlled for all other column variables. Results are based on n = 48 samples. AUDIT, Alcohol Use Disorders Identification Test; CI, confidence interval; SES,
socioeconomic status. amale = 0, female = 1; bwhite = 1, non-white = 0 cNot within 40th percentile for differential methylation, but selected a priori based on [56]. dNot within 40th percentile for differential methylation,
but selected a priori because CpG unit is located within the rs4680 SNP and present only in COMTVal allele [33]. *p < .05, **p < .01, ***p < .001, uncorrected for FWE, FDR corrected (p < .05).
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Table 4 Gene expression versus COMT methylation in
human cell lines
CpG units Spearman’s rho 95% C.I. p value
001_1 -.252 (−.923, .493) .483
001_5 -.220 (−.886, .415) .541
001_30 -.171 (−.889, .712) .636
001_32 .020 (−.837, .808) .956
001_33 -.049 (−.879, .698) .894
001_avg -.479 (−.950, .324) .162
005_4 -.377 (−.808, .401) .283
005_7 -.455 (−.920, .358) .187
005_8 -.198 (−.863, .519) .584
005_9 -.127 (−.801, .680) .726
005_10 -.206 (−.808, .615) .567
005_11 -.105 (−.801, .699) .773
005_12 -.334 (−.849, .472) .345
005_17 -.079 (−.892, .690) .828
005_18 -.421 (−.919, .377) .226
005_avg -.333 (−.796, .405) .347
006_3 -.683 (−.820, -.525) .029*
006_5 -.806 (−.968, -.245) .005**
006_9 -.782 (−.988, -.305) .008**
006_12 -.733 (−.987, -.119) .016*
006_13 -.860 (−.990, -.472) .001**
006_avg -.766 (−.963, -.082) .010*
Spearman correlation coefficients were calculated using a bootstrapping
procedure based on log relative gene expression between ABI TaqMan probes
for COMT and an 18S rRNA endogenous control with percent methylation
values for CpG units in the top 40th percentile for differential methylation
within the cell line samples. Methylation of COMT within amplicon 006 was
significantly inversely correlated with COMT expression, with coefficients
ranging from −0.683 to −0.860 (p = 0.029–0.001). Results are based on n = 10
tumors for which there were both complete methylation and gene expression
data. *p < .05, **p < .01, ***p < .001, uncorrected for FWE, FDR corrected
(p < .05).
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between sample types and by subject features. Indeed,
Figures 3B-C underscore the importance of consecutive
interrogation of CGs throughout CpG islands in that we
were able to identify transitional CpGs in amplicons 005
and 006 where the balance of methylation shifted from a
methylated to a relatively unmethylated state. Notably, we
identified significant associations with COMT Met alleles
in these transitional regions of both amplicons 005 and
006. Additionally, we identified what, to our knowledge, is
a newly described ~40 bp repeat sequence motif that be-
gins in exon 1-v2. This repeat motif spans ~1,500 bp, and
given its exonic location, is of potential significance in that
it may have an effect on MB-COMT expression. What is
certain, however, is that this repeat motif made PCR amp-
lification of the COMT_002 amplicon challenging, and
rendered amplification of COMT_004 nearly impossibledue to stuttering of Taq polymerase through multiple re-
peats over large bp distances. Thus the DM within some
regions of COMT remains unknown, although future
studies may be able to overcome this technical challenge.
Although the size of our sample of salivary DNA from
a community sample of self-identified social drinking
adults, albeit representing a continuum from light to
heavy drinkers, was not large (n = 48), we note that these
data replicate the previously reported finding of signifi-
cant DM in the putative COMT promoter region (desig-
nated amplicon COMT_006 here, particularly 006_3)
[33,56]. Like Ursini and colleagues, we found an effect of
Val158Met genotype on methylation in this promoter re-
gion, however, that study found increasing methylation
with Met allele number, whereas we observed reduced
methylation in white samples that was present only in
Met carriers, but no independent effect of Met alleles.
Discrepancies may reflect sample differences: Ursini
et al.’s sample was all white and predominantly female,
whereas ours was ethnically mixed and half female. It
could also reflect analytical strategy differences, as we
assayed at the level of individual CpGs, and evaluated
partial correlations, which controlled for effects of other
factors, while Ursini et al. did not. Our 006_avg results
may be the closest measure to theirs, and while we did
find a significant effect of Val158Met on methylation of
006_avg, our observed relationship was in the opposite
direction (less methylation with more Met alleles). Fu-
ture work with larger samples allowing for well-powered
stratification for sex and ethnicity may help resolve this
issue. The robustness of the finding of DM in the
COMT_006 region, including here in two small inde-
pendent samples, coupled with our novel finding of sig-
nificant associations between COMT_006 methylation
with COMT expression highlights the importance of fur-
ther work in this area. We also report novel associations
between methylation in COMT_001 with SES, and
COMT_003, 005, and 006 with ethnicity (Table 3), with
many of these effects interacting with Val158Met geno-
type. These latter findings indicate the importance of
controlling for these factors in future studies. Viewed in
light of reported associations with stress and both race/
ethnicity and SES (e.g. [68]), and the numerous recent
reports of interacting effects of stress and Val158Met
genotype on a large variety of conditions [33-38], differ-
ential COMT methylation state as a function of stress in
Met carriers is a plausible underlying molecular mech-
anism for these interacting associations and warrants
further study.
The relationship between DNA methylation and alco-
hol use in human samples is a topic of growing interest,
although to date, our understanding is far from complete
[39]. For example, less global DNA methylation is ob-
served in postmortem brain samples from alcoholics
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human subjects have found reduced global methylation
among ever-drinkers relative to non-drinkers [69], ele-
vated global methylation among alcoholics compared
with controls [70], or no differences in DNA methylation
based on alcohol use [71,72]. Studies investigating sites
within candidate genes have shown mixed results, al-
though together, findings suggest associations between
DNA methylation and alcohol use or alcohol use disor-
ders in human samples, although the relationships ap-
pear complex [39]. To our knowledge, only two such
studies have interrogated CpGs within the COMT gene
[73,74], which both interrogated 3 CpGs in the promoter
region (along with 381 other CpGs in other candidate
genes), finding no association between these three sites
and alcohol use. However, as we found here, such associ-
ations may interact with COMT genotype, which was
not accounted for in those studies. Specifically, we found
significant hypomethylation of amplicon 001 with increas-
ingly hazardous alcohol use only among Met carriers.
Notably, we also observed significant hypomethylation at
a locus within amplicon 001 with lower SES specific to
Met carriers. Given the finding that Met carriers show in-
creasing risk of alcoholism with greater childhood adver-
sity (which negatively correlates with SES) [35], it is
tempting to speculate that this gene × environment inter-
action could derive in part from additive hypomethylation
in the promoter regions of the COMT gene in Met car-
riers as a consequence of both childhood adversity and
high alcohol intake. Further work investigating the func-
tional consequences of such methylation is needed, al-
though our gene expression data showed a trend toward
decreased COMT expression with increasing methylation.
Thus, hypomethylation would be predicted to result in in-
creased COMT expression, reducing tonic levels of frontal
dopamine in Met carriers.
Study limitations
As noted above, amplicons COMT_005 and COMT_006
overlap or flank either a predicted or known promoter of
S-COMT. While COMT_006 methylation was strongly
inversely correlated with COMT expression, one limita-
tion of our study is that we did not have corresponding
RNA from our healthy adult saliva-derived DNA samples
with which to perform RT-PCR, nor did the commercially
available COMT TaqMan probe we used distinguish be-
tween S- and MB-COMT transcripts in our breast cancer
cell lines. Therefore, our correlations with COMT expres-
sion and methylation at specific COMT CpG loci in breast
cell lines may not generalize to any other tissue or sample
type. Future studies employing the 5’-rapid amplification
of cDNA ends (RACE) method to distinguish between
methylation of distal and proximal promoters and expres-
sion of both S- and MB-COMT transcripts in multiplehuman tissues in both affected and healthy individuals will
help resolve the relationship between COMT methylation
at particular loci and expression of distinct transcript vari-
ants [40]. Some previous work has also reported DM of
COMT in the region upstream from MB-COMT Exon 1,
with variation associated with Val158Met genotype as well
as disease states [57,58]. We did not fully interrogate this
region, but future work using the EpiTYPER® MassAR-
RAY platform to precisely quantify methylation for each
CpG unit in that region may prove fruitful.
With the exception of the proximal promoter and
Exon 1, COMT is a highly methylated gene with a dy-
namic range of methylation between 50-100%. Overall,
our findings suggest that regulation of COMT expression
is highly complex, and likely hinges on multiple factors
and interactions including the Val158Met genotype,
methylation of several loci, and a host of other biological
and environmental factors. Future work will employ
more specific gene expression probes for the S- and
MB-COMT transcripts, together with mechanistic asso-
ciation studies of locus specific DNA methylation with
transcription factor binding and higher chromatin con-
figurations with COMT.
Conclusions
In summary, we report the first comprehensive analysis of
DM within the COMT gene using precisely quantified
methylation for each CpG unit. In doing so, we have pin-
pointed specific, differentially methylated CpG sequences
that were highly informative between sample types and by
individual differences between samples. Some of these
findings solidify existing literature, while other data identi-
fies novel sites at which regulation of COMT expression
may be achieved by specific biological or environmental
factors. Given the broad function of COMT and its impli-
cation in a wide spectrum of clinical conditions, a thor-
ough understanding of how expression of this gene is
regulated may be therapeutically transformative in diseases
as diverse as alcoholism and breast cancer. The present
findings make a substantial contribution in that direction.
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